Société RXi Pharmaceuticals Corp Nasdaq
Actions
US74979C5013
Recherche biotechnologique et médicale
Métier
Dirigeants
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 15/09/17 |
Linda M. Mahoney
PRN | Corporate Officer/Principal | - | 10/11/22 |
Administrateurs
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 19/06/12 |
Director/Board Member | 73 | 02/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 18/04/13 |
Jonathan Freeman
BRD | Director/Board Member | 56 | 07/06/17 |
Robert Ferrara
BRD | Director/Board Member | 73 | 01/10/19 |
Classe d'actions
Vote | Nombre | Flottant | Autocontrôle | Flottant Total | |
---|---|---|---|---|---|
Action A | 1 | 4 591 700 | 4 564 638 ( 99,41 %) | 0 | 99,41 % |
Coordonnées société
Phio Pharmaceuticals Corp.
11 Apex Drive Suite 300A PMB 2006
01752, Marlborough
+508-767-3861
http://www.phiopharma.comSecteur
Varia. 1 janv. | Capi. | |
---|---|---|
+33,63% | 50,85 Md | |
-0,09% | 42,82 Md | |
+49,62% | 42,03 Md | |
-4,96% | 29,55 Md | |
+11,18% | 26,11 Md | |
-21,95% | 19,13 Md | |
+8,61% | 13,05 Md | |
+28,31% | 12,16 Md | |
+24,73% | 12,08 Md |